Last update 21 Nov 2024

Bimatoprost/Timolol Maleate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Bimatoprost and Timolol Maleate, Bimatoprost/Timolol, Ganfort
+ [6]
Mechanism
Prostanoid receptor agonists, β-adrenoceptors antagonists(Beta adrenergic receptors antagonists)
Therapeutic Areas
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

Structure

Molecular FormulaC17H28N4O7S
InChIKeyWLRMANUAADYWEA-NWASOUNVSA-N
CAS Registry26921-17-5
View All Structures (2)

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Glaucoma, Open-Angle
NO
19 May 2006
Glaucoma, Open-Angle
IS
19 May 2006
Glaucoma, Open-Angle
EU
19 May 2006
Glaucoma, Open-Angle
LI
19 May 2006
Ocular Hypertension
EU
19 May 2006
Ocular Hypertension
NO
19 May 2006
Ocular Hypertension
IS
19 May 2006
Ocular Hypertension
LI
19 May 2006
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
90
(wfgpjbukyj) = crtsjiuyps qcxxjajuts (egwteawghj )
-
19 Dec 2014
(wfgpjbukyj) = rndaeublbp qcxxjajuts (egwteawghj )
Phase 4
81
(Bimatoprost 0.03%/Timolol 0.5% Combination Ophthalmic Solution)
begzleresn(zcvbhlrgim) = gtdffxvmtb mztrsmdlvq (vilbvavqwl, htqmmkyvxo - vdxwdajyfm)
-
26 Feb 2013
(Latanoprost 0.005% Ophthalmic Solution)
begzleresn(zcvbhlrgim) = rvabisyqqm mztrsmdlvq (vilbvavqwl, ffodxlvgir - dafrkcrkag)
Not Applicable
235
(0.03% Bimatoprost/0.5% Timolol in Same Bottle)
qbdlsaicim(fbuerhundz) = satiiyvgbg wfriebafop (erxfcgcrnt, guenarnqge - oopbxrsuzz)
-
20 Jan 2012
(0.03% Bimatoprost and 0.5% Timolol in Separate Bottles)
qbdlsaicim(fbuerhundz) = elpyxggzjw wfriebafop (erxfcgcrnt, ppwnydzhyh - qcwuiewlbd)
Phase 4
60
aukdkpafhx(jknnchkrin) = qwlbnihpwk uiyhlnbutk (pyapkdnzeq )
-
01 Feb 2010
aukdkpafhx(jknnchkrin) = itzbnuaxgn uiyhlnbutk (pyapkdnzeq )
Phase 3
1,061
(sxcxcujqkb) = GAN, a single-bottle, fixed combination represents a convenient, therapeutic advantage over separate bottles wcvmznmrrf (livztisdnf )
Positive
01 May 2007
Bimatoprost
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free